Geary Michael B, Orner Caitlin A, Bawany Fatima, Awad Hani A, Hammert Warren C, O'Keefe Regis J, Loiselle Alayna E
Center for Musculoskeletal Research, University of Rochester, Rochester, New York, United States of America; School of Medicine and Dentistry, University of Rochester, Rochester, New York, United States of America.
Center for Musculoskeletal Research, University of Rochester, Rochester, New York, United States of America.
PLoS One. 2015 Aug 27;10(8):e0136351. doi: 10.1371/journal.pone.0136351. eCollection 2015.
Flexor tendon injuries are a common clinical problem, and repairs are frequently complicated by post-operative adhesions forming between the tendon and surrounding soft tissue. Prostaglandin E2 and the EP4 receptor have been implicated in this process following tendon injury; thus, we hypothesized that inhibiting EP4 after tendon injury would attenuate adhesion formation. A model of flexor tendon laceration and repair was utilized in C57BL/6J female mice to evaluate the effects of EP4 inhibition on adhesion formation and matrix deposition during flexor tendon repair. Systemic EP4 antagonist or vehicle control was given by intraperitoneal injection during the late proliferative phase of healing, and outcomes were analyzed for range of motion, biomechanics, histology, and genetic changes. Repairs treated with an EP4 antagonist demonstrated significant decreases in range of motion with increased resistance to gliding within the first three weeks after injury, suggesting greater adhesion formation. Histologic analysis of the repair site revealed a more robust granulation zone in the EP4 antagonist treated repairs, with early polarization for type III collagen by picrosirius red staining, findings consistent with functional outcomes. RT-PCR analysis demonstrated accelerated peaks in F4/80 and type III collagen (Col3a1) expression in the antagonist group, along with decreases in type I collagen (Col1a1). Mmp9 expression was significantly increased after discontinuing the antagonist, consistent with its role in mediating adhesion formation. Mmp2, which contributes to repair site remodeling, increases steadily between 10 and 28 days post-repair in the EP4 antagonist group, consistent with the increased matrix and granulation zones requiring remodeling in these repairs. These findings suggest that systemic EP4 antagonism leads to increased adhesion formation and matrix deposition during flexor tendon healing. Counter to our hypothesis that EP4 antagonism would improve the healing phenotype, these results highlight the complex role of EP4 signaling during tendon repair.
屈肌腱损伤是常见的临床问题,修复术后肌腱与周围软组织之间常形成粘连,导致修复复杂化。肌腱损伤后,前列腺素E2和EP4受体参与了这一过程;因此,我们推测肌腱损伤后抑制EP4可减轻粘连形成。利用C57BL/6J雌性小鼠的屈肌腱撕裂和修复模型,评估EP4抑制对屈肌腱修复过程中粘连形成和基质沉积的影响。在愈合的增殖后期通过腹腔注射给予全身性EP4拮抗剂或载体对照,并分析活动范围、生物力学、组织学和基因变化等结果。用EP4拮抗剂治疗的修复在损伤后的前三周内活动范围显著减小,滑行阻力增加,提示粘连形成增多。修复部位的组织学分析显示,用EP4拮抗剂治疗的修复有更旺盛的肉芽组织区,经天狼星红染色显示III型胶原早期极化,这些结果与功能结果一致。逆转录聚合酶链反应分析表明,拮抗剂组中F4/80和III型胶原(Col3a1)表达加速达到峰值,同时I型胶原(Col1a1)表达下降。停用拮抗剂后基质金属蛋白酶9(Mmp9)表达显著增加,与其在介导粘连形成中的作用一致。参与修复部位重塑的基质金属蛋白酶2(Mmp2)在EP4拮抗剂组修复后10至28天之间稳步增加,这与这些修复中需要重塑的增加的基质和肉芽组织区一致。这些发现表明,全身性EP4拮抗作用会导致屈肌腱愈合过程中粘连形成和基质沉积增加。与我们认为EP4拮抗作用会改善愈合表型的假设相反,这些结果突出了EP4信号在肌腱修复过程中的复杂作用。